Jointly provided by Purdue University and Physicians' Education Resource®, LLC (PER®)
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
Physicians’ Education Resource®, LLC, (PER®) is pleased to present the CME-certified online activity titled "Advancing the Role of the SGLT2 Inhibitors in the T2D Treatment Paradigm." This innovative activity is an archived version of the live-streamed Medical Crossfire® held on June 25, 2018 at the American Diabetes Association’s 78th Scientific Sessions.
This activity is directed to endocrinologists.
After completing this activity, clinicians should be better able to:
Articulate reasons that persons with type 2 diabetes (T2D) fail to achieve target A1C goals and reduce cardiometabolic risk factors
List the potential clinical benefits for achieving glycemic control with newer therapies, especially SGLT2 inhibitors, in persons with T2D and cardiometabolic risk factors at various stages of the disease
Discuss results of recent large-scale cardiovascular outcomes trials in persons with T2D
Develop individualized approaches for effectively improving outcomes in persons with T2D and cardiometabolic risk factors
Conflict Of Interest Disclosure Policy
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships will be made in writing to the audience prior to the activity.
Program Chair Vivian Fonseca, MD Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center New Orleans, LA
Dr. Fonseca discloses the following: Grant/Research Support: Asahi, Bayer, Boehringer Ingelheim Consultant/Speakers Bureau: AstraZzeneca, BI Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda; Other/Honoraria for CME Lectures: AstraZzeneca, BI Lilly, Intarcia, Novo Nordisk, Sanofi-Aventis, Takeda
Program Moderator Stephen Brunton Executive Director Primary Care Metabolic Group (PCMG ) Palm Springs, CA
Dr. Brunton discloses the following: Consultant/Speaker’s Bureau: Abbott Diabetes, AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, Sanofi
Program Faculty Silvio E. Inzucchi, MD Professor of Medicine Clinical Chief, Endocrinology Yale School of Medicine Medical Director, Yale Diabetes Center Yale-New Haven Hospital New Haven, CT
Dr. Inzucchi discloses the following: Consultant/Speaker’s Bureau: Janssen, VTV Pharmaceuticals Other/Honoraria for CME Lectures: Clinical trial/steering/executive/publications committees: Astra Zeneca, Boehringer Ingelheim, Eisai (TIMI), Novo Nordisk, Sanofi/Lexicon Data Monitoring Committee: Intarcia
James Januzzi, MD Hutter Family Professor of Medicine Harvard Medical School Physician Massachusetts General Hospital Cardiometabolic Trials Baim Institute for Clinical Research Boston, MA
Dr. Januzzi discloses the following: Grant/Research Support: Boehringer Ingelheim, Janssen Consultant/Speakers Bureau: Janssen
Accredited Provider Disclosure
All additional planning committee members, staff and reviewers of Purdue University College of Pharmacy have no relevant financial relationships with commercial interests to disclose.
Publishing Staff Disclosures
All additional planning committee members, staff and reviewers of Physicians' Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Physician’s Education Resource, LLC. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.
Purdue University College of Pharmacy designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.
Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about the accreditation of this program, please contact Dawn Sinclair, email@example.com, Accreditation Coordinator for Purdue University College of Pharmacy’s Office of CE, regarding accreditation designation or Heather Holley, firstname.lastname@example.org, Reconciliation and Outcomes Coordinator for Purdue University College of Pharmacy’s Office of CE, regarding CE credit received and/or certificates.